



Date: 14.08.2021

To,
The General Manager,
Listing Department,
Bombay Stock Exchange
1st Floor, New trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai-400001

Dear Sir/Madam,

Sub: Financial Results for quarter ended 30.06.2021-Regulation 33

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting through Video Conferencing held on Saturday, 14th August, 2021 at 11:30 A.M, interalia considered and approved the unaudited Financial Results for the quarter ended 30th June, 2021

Copy of Unaudited Financial Results for the quarter ended 30.06.2021 is enclosed herewith

Kindly take the same on record and acknowledge the receipt of same.

Thanking You
For Godavari Drugs Limited

Rashmi Agarwal
Company Secretary & Compliance Officer



Independent Auditor's Review Report on unaudited quarterly financial results of Godavari Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Godavari Drugs Limited

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and three months ended June 30, 2021 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Sridhar & Co.,
Chartered Accountants
FRN: 006206S


Vemulapati Sridhar
Proprietor

ICAI Membership No. 202337
Hyderabad. August 14, 2021.
UDIN: 21202337AAAADH4475



GODAVARI DRUGS LIMITED

CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

Sl. No.	Particulars	(Rs. In Lakhs)			
		Quarter ended			Year ended
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	Revenue from operations	4440.18	3295.84	2569.22	12267.01
2	Other Income	1.70	11.40	0.93	41.01
3	Total Revenue from operations (1+2)	4441.88	3307.24	2570.15	12308.02
4	Expenses				
	(a) Cost of materials consumed	3663.10	2429.23	2385.40	9414.80
	(b) Changes in inventories of finished goods & work-in-progress	-87.75	102.55	-395.73	244.02
	(c) Employee benefits expense	118.14	119.15	77.78	394.31
	(d) Depreciation & amortization expense	41.75	37.49	27.85	122.27
	(e) Finance Costs	71.26	81.05	84.88	330.80
	(f) Other Expenses	437.07	388.23	275.06	1231.18
	Total expenses	4243.57	3157.70	2455.24	11737.38
5	Profit before exceptional Items and tax (3-4)	198.31	149.54	114.91	570.64
6	Exceptional items				
7	Profit before Tax (5-6)	198.31	149.54	114.91	570.64
8	Tax expense	-55.88	-20.90	-29.84	-157.83
9	Net Profit for the period (7-8)	142.43	128.64	85.07	412.81
10	Other Comprehensive Income				
11	Total Comprehensive Income (9+10)	142.43	128.64	85.07	412.81
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05
13	Other Equity(Reserves and Surplus)	0	1685.56	0.00	1685.56
14	Earnings per share (of Rs.10/- each) (not annualized)				
	(a) Basic	1.89	1.71	1.13	5.48
	(b) Diluted	1.89	1.71	1.13	5.48

Notes:

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14th August 2021.
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

K.K.Jain
K.K.Jain
Director Finance
DIN: 00076657



Place: Secunderabad
Date: 14-08-2021